Pharming to Present Multiple Studies at 2026 Clinical Immunology Society Annual Meeting

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: 1 day ago

0mins

PHAR-26.83%

Should l Buy PHAR?

Source: NASDAQ.COM

Presentation Schedule: Pharming Group N.V. will deliver multiple scientific presentations at the Clinical Immunology Society Annual Meeting from May 6-9, 2026, in New Orleans, showcasing new data on Leniolisib in pediatric patients with activated phosphoinositide 3-kinase delta syndrome (APDS).
Focus on Pediatric Study: One presentation will concentrate on interim safety and efficacy outcomes from an open-label long-term extension study in children aged 4-11, supporting Pharming's efforts to expand treatment access beyond the currently approved age group.
Clinical Experience Data: Additional presentations will describe real-world and clinical experience data in Common Variable Immunodeficiency (CVID) and related immune dysregulation disorders, findings from the APDS-CHOIR registry, and caregiver and clinician-reported symptom assessments in pediatric APDS.
Ongoing Study Design: Pharming and its academic collaborators will also present the design and baseline characteristics of an ongoing Phase 2 study evaluating Leniolisib in primary immunodeficiencies with enhanced PI3K pathway signaling.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PHAR?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PHAR

Wall Street analysts forecast PHAR stock price to rise

2 Analyst Rating

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 12.000

Low

37.00

Averages

39.50

High

42.00

Current: 12.000

Low

37.00

Averages

39.50

High

42.00

Oppenheimer

Outperform

maintain

$41 -> $40

2026-05-08

New

Reason

Oppenheimer

Price Target

$41 -> $40

AI Analysis

2026-05-08

New

maintain

Outperform

Reason

Oppenheimer lowered the firm's price target on Pharming to $40 from $41 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 results with Ruconest revenues taking a larger than anticipated seasonal hit, driving disappointing Q1 top-line revenues of $72.4M vs. estimates. Given the magnitude of the seasonal revenue fall off compared to last year, Oppenheimer sees meeting guidance as a challenge with management reiterating prior full year guidance of $405M-$415M.

Canaccord

Whitney Ijem

initiated

$37

2026-04-10

Reason

Canaccord

Whitney Ijem

Price Target

$37

2026-04-10

initiated

Reason

As previously reported, Canaccord analyst Whitney Ijem initiated coverage of Pharming with a Buy rating and $37 price target. Lead product Ruconest, a complex biologic approved in the U.S. since 2014 for the on-demand treatment of hereditary angioedema attacks, will see its IP expire in 2026 and the HAE competitive landscape is evolving, notes the analyst. However, the firm continues to model growth in the near-to-medium term, given that it doesn't anticipate biosimilar competition given the proprietary, transgenic rabbit-based manufacturing process and Ruconest's high-efficacy product profile, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PHAR

Unlock Now

About PHAR

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Pharming Presents Research Findings at CIS Annual Meeting

1 day agoNewsfilter

Clinical Research Progress: Pharming showcased interim results from a long-term extension study of leniolisib for pediatric patients with APDS at the 2026 CIS Annual Meeting, indicating the drug's potential in improving immune function and offering new treatment options for patients.
Clinical Trial Updates: Two Phase II clinical trials are currently underway to evaluate the safety and tolerability of leniolisib in patients with CVID and other immune dysregulation disorders, with results expected in the second half of this year, providing crucial data for further drug development.
Diverse Research Topics: The meeting will also present clinical experiences using leniolisib in patients with CVID and CVID-like disorders, further revealing clinical characteristics of APDS and other primary immunodeficiencies, potentially advancing research in related fields.
Company Strategic Direction: Pharming's Chief Medical Officer Anurag Relan noted that the data presented will enhance understanding of APDS and other immune dysregulations, reflecting the company's ongoing commitment to rare disease treatments, which may bolster investor confidence.

Pharming Releases 2026 Financial Guidance Amid Revenue Decline

1 day agoseekingalpha

Revenue Decline: Pharming reported Q1 revenue of $72.4 million, an 8.5% year-over-year decrease that missed expectations by $19.67 million, primarily due to RUCONEST inventory drawdowns and exit from non-U.S. markets, indicating weakened market demand.
Positive Cash Flow: Despite the revenue drop, Pharming achieved a positive operating cash flow of $2.0 million, reflecting the company's ongoing efforts in cost management and financial discipline, which helps maintain operational stability.
Liquidity Position: As of the reporting period, Pharming had cash and marketable securities totaling $171.8 million, down $9.3 million from FY25, mainly due to a $12.3 million expense from DSP lease termination, indicating liquidity pressure.
2026 Financial Guidance: Pharming projects total revenues for FY 2026 to be between $405 million and $425 million, with an expected growth rate of 8% to 13%, and plans to invest $60 million in R&D to advance its pipeline, demonstrating confidence in future growth.